Menu
IDWeek 2023 Post Show Hero Image

Thank you for visiting Karius during IDWeek™ 2023! We'll see you in Los Angeles in 2024!

Presentation Theater:

The Power of Plasma Microbial Cell-Free DNA: Real World Application of a Liquid Biopsy for Infectious Disease

Join us for an informative panel discussion on metagenomic next-generation sequencing (mNGS) of plasma microbial cell-free DNA (mcfDNA) as a diagnostic tool for infectious disease.

This engaging discussion will bring together physicians from various infectious disease specialties at leading medical centers across the US to share their expertise and experiences utilizing this technology in clinical practice. Our panelists will explore the clinical and economic value considerations of this technology, while also addressing the challenges that come with it. Through expert insights, real-world case studies, and practical knowledge, attendees will gain an understanding of the considerations for implementing and effectively using the Karius Test in their clinical practice.




Speakers

Speaker 1

Moderator:
Samuel Dominguez, MD, PHD
Children's Hospital Colorado

Speaker 2

Panelist:
Christopher Cooper, MD
Infectious Disease Consultants, Orlando, FL

Speaker 4

Panelist:
Megan Morales, MD
Virginia Commonwealth University

Highlighted Abstracts & Oral Presentations

(870) Plasma microbial cell-free DNA sequencing impacts antimicrobial management in immunocompromised patients with pneumonia
Presenting Author: Thomas L. Holland, MD, Duke University Medical Center
Read abstract
(872) Characterizing Plasma Microbial Cell-Free DNA Sequencing Detections of Public Health Important Pathogens
Presenting Author: Sarah Y. Park, MD, Karius
Read abstract
(873) Detection of Monkeypox Virus Using Microbial Cell-free DNA: Demonstrating the Potential of Agnostic Sequencing for Real Time Identification of an Emerging Pathogen
Presenting Author: Sarah Y. Park, MD, Karius
Read abstract
(983) Use of plasma-based microbial cell-free DNA (mcfDNA) sequencing for surveillance of infection in the 1st month after lung transplant (LT): a prospective, observational, pilot study
Presenting Author: Ghady Haidar, MD, University of Pittsburgh School of Medicine
Read abstract
Go to the Interactive Program

The results of the PICKUP Study have been published in Clinical Infectious Diseases.

What is the Karius Test?

The Karius Test is a blood test, based on metagenomic next-generation sequencing (mNGS) of plasma microbial cell-free DNA (mcfDNA). From a single blood sample, the Karius Test can rapidly and non-invasively detect over one thousand pathogens associated with deep-seated and bloodstream infections.

AMR Final Icon NEW ANTIMICROBIAL RESISTANCE DETECTION

In addition to detecting over 1,000 pathogens from blood, the Karius Test now offers a culture-independent method of detection for common AMR markers for 4 classes of antimicrobials across 18 bacterial pathogens:

  • Methicillin-resistant Staphylococci (SCCmec, mecA, mecC)
  • Vancomycin-resistant Enterococci (vanA, vanB)
  • Carbapenem-resistant Gram-negative bacteria (KPC)
  • Extended spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria (CTX-M)

1 blood sample  |  1-day processing*  |  1000+ pathogens

Main Diagnostic Applications

Pneumonia_Use Case
Pneumonia
Febrile Neutropenia_Use Case

Febrile neutropenia

KARIUS_TrifoldIcons_v4_KARIUS_Endocarditis_Icon_WhiteColor

Endocarditis

KARIUS_TrifoldIcons_v4_KARIUS_Invasive Fungal Infection_Icon_WhiteColor

Invasive fungal infections

*The Karius Test provides pathogen detection results typically one day after sample receipt, with AMR marker determination available within one day after pathogen results.

The Karius Test® is a laboratory-developed test. The Karius Laboratory is certified under CLIA and accredited by CAP.

Stay up-to-date with Karius

Sign up today to receive notification of future real-world cases of the Karius Test being used by physicians and upcoming events.